Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06GKR
|
|||
| Drug Name |
Deferoxamine
|
|||
| Synonyms |
deferoxamine; Desferrioxamine B; DESFERRIOXAMINE; Deferoxamine B; Deferrioxamine B; 70-51-9; Deferrioxamine; Deferoxamin; Deferoxaminum; DFOM; Desferin; Desferral; Desferrin; Desferex; Desferan; N-Benzoylferrioxamine B; Desferal; DF B; DFOA; Deferoxamide B; Deferoxamina; NSC-527604; Ferrioxamine B, N-benzoyl-; Desferriferrioxamin B; UNII-J06Y7MXW4D; Deferoxamine [USAN:INN]; Deferoxaminum [INN-Latin]; Deferoxamina ; Deferoxamine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acute iron or aluminum toxicity [ICD-11: FB83.20; ICD-10: M83.4] | Approved | [1] | |
| Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Phase 1/2 | [2] | ||
| Therapeutic Class |
Antiviral Agents
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C25H48N6O8
|
|||
| Canonical SMILES |
CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O
|
|||
| InChI |
1S/C25H48N6O8/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34)
|
|||
| InChIKey |
UBQYURCVBFRUQT-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 70-51-9
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:4356
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 207384. | |||
| REF 2 | ClinicalTrials.gov (NCT04333550) Application of Desferal to Treat COVID-19. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.